Citron Research Reports On Apellis Pharmaceuticals (APLS); Says "Happy Days Are OVER For Apellis, As The Experts Give A Thumbs Down To
Syfovre. Citron Expects FDA Warning Letter."
Portfolio Pulse from Benzinga Newsdesk
Citron Research has released a report on Apellis Pharmaceuticals (APLS), stating that the company's successful days are over due to concerns over its drug, Syfovre. The drug, used for treating Geographic Atrophy, has been linked to retinal vasculitis, a side effect that has caused the company's stock to drop. Despite these reports, Apellis continues to stand by the safety of Syfovre.
November 06, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock may continue to be negatively impacted due to concerns over its drug, Syfovre. The drug has been linked to retinal vasculitis, a side effect that has already caused a drop in the company's stock.
The report from Citron Research, a well-known short-seller, has raised serious concerns about the safety of Apellis' drug, Syfovre. This has already caused a drop in the company's stock and may continue to do so as the company faces potential regulatory scrutiny and loss of public trust. The company's insistence on the safety of the drug despite these reports may further erode investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100